ClinicalTrials.gg
CompletedNCT01925157Updated Oct 1, 2015

A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)

A Phase 1 interventional study of LY3090106 - SQ and LY3090106 - IV in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 4 sites in 4 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-01.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Eli Lilly and Company.

Enrollment
27th of 35
43 · median 164
Started
2013
with 2 others
Phase 1
8 of 35
2 open now
Registered
25th of 35
by date

Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, this one is the 27th largest by enrollment, is one of 3 that started in 2013, is one of 8 in phase 1, and was the 25th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3090106 in healthy participants and in participants with RA who are having an inadequate response to methotrexate (MTX). The study will investigate how the body processes the study drug and how the study drug affects the body. The study will last about 3 months for each participant.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Healthy Participants:

  • Males or non-pregnant females age 18 to 65 years
  • (BMI) of 18.5 to 32.0 kilograms per meter squared (kg/m\^2)

Inclusion Criteria for Participants for RA:

  • Diagnosis of at least mildly active adult-onset RA
  • Positive anti-citrullinated protein (ACPA) antibodies or rheumatoid factor
  • Regular use of MTX for at least 12 weeks and at a stable dose (10 to 25 mg/week) for at least 4 weeks prior to baseline
  • American College of Rheumatology (ACR) Functional Class I, II or III

Exclusion Criteria for Healthy Participants:

  • Have received biologic agents within 3 months or 5 half-lives
  • Have surgery within 12 weeks prior to screening
  • Known history of (HIV infection and/or positive human HIV antibodies)
  • Have evidence of, or test positive for, virus or virus
  • Have evidence of active infection or fever
  • Have donated greater than 500 mL blood within 30 days prior to screening
  • Smoke greater than 10 cigarettes/day or equivalent
  • Have received within 1 month of screening
  • Have a history of allergy to monoclonal antibodies or severe drug allergies

Exclusion Criteria for Participants with RA:

  • Have received prior or current treatment with biologic RA therapies
  • Have received a live vaccine 28 days prior to screening or intend to receive a live vaccine during the course of the study
  • \< 10 grams per deciliter (g/dL), count \< 100,000 cells/microliter (uL), total white blood cell count \< 3000 cells/uL, \< 2000 cells/uL, or lymphocyte count \< 500 cells/uL
  • (AST) > 1.5 x upper limit or the normal range (), alanine transamine (ALT) > 1.5 x ULN, creatinine > 1.5 mg/dL (114 micromoles/liter [uMol/L])
  • Treatment with > 10 mg/day or unstable dose of oral prednisone or equivalent within 28 days of baseline
  • Have required an increase in dose or a new prescription of narcotic within 28 days prior to randomization
  • Have received any parenteral within 28 days before screening
  • Treatment with any oral disease-modifying anti-rheumatic drugs (DMARDs) other than MTX within 4 weeks prior to baseline
  • Any neurological, psychiatric, vascular, or system disorder that could also affect the evaluation of disease activity assessments. Anemia of chronic disease is allowed if hemoglobin > 10 g/dL
  • Have rheumatic or systemic disease other than RA or significant active systemic involvement secondary to RA. Participants with secondary Sjogren's syndrome are eligible.
  • Uncontrolled arterial hypertension characterized by a confirmed systolic blood pressure of > 150 mm Hg or diastolic blood pressure > 90 mm Hg at screening or on day of study drug dosing
  • Poorly controlled diabetes as defined by glycosylated hemoglobin () > 8.0% at screening
  • Known history of human immunodeficiency virus (HIV infection and/or positive human HIV antibodies)
  • Have evidence of, or test positive for, hepatitis C virus or hepatitis B virus
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    LY3090106 (Healthy)

    Healthy participants will receive a single dose of LY3090106 in dose escalation cohorts subcutaneously (SQ).

    Biological: LY3090106 - SQ

  • Placebo comparator
    Placebo (Healthy)

    Healthy participants will receive a single dose of placebo matching LY3090106 SQ.

    Biological: Placebo - SQ

  • Experimental
    LY3090106 (RA)

    Participants with RA will receive a single dose of LY3090106 in dose escalation cohorts SQ or intravenously (IV).

    Biological: LY3090106 - SQ · Biological: LY3090106 - IV

  • Placebo comparator
    Placebo (RA)

    Participants with RA will receive a single dose of placebo matching LY3090106 SQ.

    Biological: Placebo - SQ

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration

    Time frame: Baseline through 12 weeks

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY3090106

    Time frame: Predose through 12 Weeks

  2. Number of Participants with Anti-LY3090106 Antibodies

    Time frame: Baseline through 12 Weeks

  3. Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3090106

    Time frame: Predose through 12 Weeks

07

Study locations

4 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sofia, 1612, Bulgaria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chisinau, MD2025, Moldova, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bydgoszcz, 85-168, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucharest, 50159, Romania
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Jan 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2013
First posted
Aug 19, 2013
Start
Aug 2013
Primary completionActual
Jan 2015
CompletionActual
Sep 2015
Last update
Oct 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01925157
Responsible party
Sponsor
First posted
Aug 19, 2013
Start date
Aug 2013
Primary completion
Jan 2015
Completion
Sep 2015
Last update
Oct 1, 2015

Study contacts

Call 1-877-CTLilly (1-877-285-4459) or 1-317-615-4559 Mon - Fri 9AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tibulizumab

Start the discussion